AstraZeneca has entered into a definitive agreement to acquire Boston-based Modella AI, a leader in physics-driven machine-learning platforms for molecular and materials modeling. Founded in 2018, Modella AI’s proprietary framework combines high-performance computing with deep learning to predict molecular interactions at atomic resolution. The transaction is structured as a cash purchase and is expected to close in Q2 2026, pending customary regulatory approvals.

The acquisition accelerates AstraZeneca’s long-standing commitment to digital innovation in drug discovery, particularly in oncology. Modella AI’s platform will be integrated into AstraZeneca’s Early Translational Science organization to enhance lead optimization, reduce synthetic iteration cycles by up to 50%, and anticipate off-target liabilities earlier in preclinical development. AstraZeneca’s R&D budget exceeded $9 billion in 2024, and the addition of Modella AI is projected to improve compound progression metrics across multiple therapeutic areas.

By embedding Modella AI’s tools into its discovery workflows, AstraZeneca expects to advance at least three new oncology candidates into IND-enabling studies by 2027. The combined team will focus initially on kinase inhibitors and antibody–drug conjugates, leveraging predictive atomistic simulations to tailor binding kinetics and improve candidate selectivity. This capability supports AstraZeneca’s goal of shortening the average preclinical development timeline from 24 months to under 18 months, reinforcing its position as a leader in AI-driven biopharma innovation.